Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RVF MP-12 Vaccine
NCT00415051Phase 2Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Aug 2006
- Primary completion
- May 2008
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RVF MP-12 in Rift Valley fever (RVF), sponsored by U.S. Army Medical Research and Development Command. Primary endpoint: Number of Adverse Events at 1 year. Started Aug 2006; status: completed.
02
Drugs
RVF MP-12
03
Conditions
Rift Valley fever (RVF)
Beyond the preview
Go deeper on NCT00415051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00415051.